Browse the evidence

At average weight loss, the effect of a higher PS amounted to a change of 0.20-0.28 cm per standard deviation in WCadjBMI.

The small effect size suggests that genetic factors may have limited practical implications for weight loss interventions.

Plant-based diets improve cardiovascular health by modulating gut microbiota and metabolites.

Practitioners may consider recommending plant-based diets for cardiovascular health.

A stronger decline in sACE2 during the diet intervention was independently associated with improvements in metabolic health markers.

Improvements in metabolic health may be linked to changes in sACE2 levels during weight loss.

Early genetic diagnostics can identify the type of obesity and guide therapy options.

Implementing genetic testing can enhance personalized treatment strategies for obesity.

GLP-1 receptor agonists and dual incretin agonists provide clinically significant benefits in weight reduction, blood pressure modulation, lipid profile improvement, and cardiovascular risk mitigation.

Practitioners can consider GLP-1 receptor agonists and dual agonists as effective options for managing weight and cardiovascular health in patients with T2DM and obesity.

Consumption of ultra-processed foods (UPFs) is associated with increased cardiovascular (CV) risk.

Clinicians should consider the impact of UPFs when advising patients on cardiovascular health.

Excessive carbohydrate intake has noxious effects on human health, referred to as 'carbotoxicity.'

Practitioners should consider the negative health impacts of excessive carbohydrate consumption.

Reducing carbohydrate intake has beneficial effects on health.

Reducing carbohydrate intake may improve health outcomes.

Improving insulin sensitivity is anticipated to lower plasma glucose concentration and decrease CVD risk in T2DM patients, independent of glucose control.

Enhancing insulin sensitivity can be a key strategy in T2DM management.

Modified probiotic strains and supraphysiological dosages of microbial metabolites may be beneficial in combatting obesity.

Consider using modified probiotics and microbial metabolites in obesity treatment strategies.

Cherries have antioxidant and anti-inflammatory properties.

Including cherries in the diet may help reduce oxidative stress and inflammation.

Defined diets have been tested as preventive and treatment approaches for diseases such as epilepsy, ulcerative colitis, Crohn disease, and type 1 diabetes mellitus.

Defined diets may be considered in clinical settings for managing specific diseases.

Yoga intervention for 10 weeks significantly reduced DNA damage indicators in T2D subjects, including Tail Moment (-5.88; P = .013) and Olive Tail Moment (-2.93; P < .01).

Yoga may be an effective intervention for reducing DNA damage in individuals with type 2 diabetes.

Ultra-processed foods (UPFs) may be associated with obesity and asthma.

Reducing UPF consumption may benefit individuals at risk for obesity and asthma.

Obesity and diabetes mellitus are major risk factors for the development and progression of chronic kidney disease (CKD).

Healthcare providers should prioritize screening for CKD in patients with obesity and diabetes.

IgG antibody concentrations decreased in 83% of the targeted foods in the treatment group.

Targeted elimination diets may effectively reduce IgG levels for specific foods.

Caloric restriction-induced transcriptional reprogramming in adipose tissue implicated pathways regulating mitochondrial bioenergetics, anti-inflammatory responses, and longevity.

Caloric restriction may promote metabolic health through specific molecular pathways.

Reduction of PLA2G7 may mediate the immunometabolic effects of caloric restriction and could potentially lower inflammation and extend health span.

Targeting PLA2G7 may be a strategy to reduce inflammation and improve health span.

Neither glycogen depletion nor phosphorylation of relevant signalling proteins showed any difference between conditions of load and repetition duration.

Resistance training outcomes are not influenced by glycogen depletion or signalling protein changes based on load or repetition duration.

Current pharmacologic options for obesity management are largely limited in number and of modest efficacy/safety profile.

Practitioners should be aware of the limitations of existing obesity medications.

There is an urgent need for safe and more efficacious new agents for obesity treatment.

There is a pressing need for practitioners to seek out and consider new treatment options.

Emerging pharmacologic agents and alternative approaches targeting obesity pathways are being explored.

Practitioners should stay informed about new pharmacologic agents and alternative approaches in obesity treatment.

SCD1 is a key enzyme that regulates energy homeostasis and various physiological processes.

Understanding SCD1's role can help in targeting metabolic diseases.

Aberrant activation of SCD1 contributes to obesity, non-alcoholic fatty liver, diabetes, and cancer.

Targeting SCD1 may help in managing these metabolic diseases.